Dr. Arbour is an assistant professor at Memorial Sloan Kettering Cancer Center where she is a member of the Thoracic Oncology Service. She is board certified in medical oncology and takes a special interest in lung cancer and precision oncology. She is actively involved in developing and overseeing clinical trials of molecular targeted therapies in non-small cell lung cancer. Her research interests also include the use of molecular testing to evaluate for potential prognostic and predictive effects of co-occurring somatic genomic alterations in lung cancer. Dr. Arbour received her M.D. from Cornell University, completed her residency at New York-Presbyterian Hospital-Cornell, and her fellowship training at Memorial Sloan Kettering Cancer Center.
Professor Ashley’s career in cancer research dates more than two decades. He is credentialed in both pediatric and adult neuro-oncology practice, and this has been the focus of his efforts in translational research and leadership. His peer-reviewed publication record is diverse and includes laboratory-based cancer research, clinical trials, as well as public-health and psycho-oncology research. His primary research focus is on the immunology, epigenetics and genetics of brain tumors. His achievements in research have led to change in practice in the care of both children and adults with brain tumors.
Ashley is highly regarded for his work, as evidenced by numerous awards and invitations to plenary sessions and symposia of international standing. He has been the principal investigator of a number of important national and international studies both clinical and pre-clinical. He is recognized as a senior figure and opinion leader in academic medicine nationally and internationally.
Dr. Church is a board-certified Pediatric Pathologist and Molecular Genetic Pathologist. She is the Associate Director of the Laboratory for Molecular Pediatric Pathology (LaMPP) at Boston Children’s Hospital, and an Instructor at Harvard Medical School. She has participated in several high-impact studies using molecular profiling to support the care of children with cancer, including the iCat study, Profile study, and the ongoing multi-institutional GAIN consortium study.
Dr. Del Vecchio Fitz has extensive experience in translational cancer research and clinical genomics. She is currently the owner and Principal at Precision Oncology Consulting, LLC and Director of Life Sciences Program Development at the Institute for Digital Engineering and Life Sciences in Portland, ME. Previously at Dana-Farber Cancer Institute, she led initiatives to build precision medicine software platforms, including a computational tool for matching patient-specific genomics profiles to clinical trials. She has also worked as Principal Scientist at N-of-One, Inc., providing clinical interpretation of molecular tests in order to improve treatment options and outcomes for cancer patients. Dr. Del Vecchio Fitz grew up in Maine and earned her Bachelor’s degree in biology from Bowdoin College. She completed her Ph.D. in cancer biology and Masters of Science in Medicine at Stanford University, and postdoctoral training at the Whitehead Institute of MIT.
Dr. Do practices in the Early Drug Development Center, Dana-Farber Cancer Institute and oversees the care of patients enrolled in early phase clinical trials. Dr. Do received her M.D. from George Washington University (GWU), followed by a residency at GWU, and a fellowship at the National Cancer Institute, National Institutes of Health.
Dr. DuBois completed medical school and pediatric training at the University of California, San Francisco (UCSF). He completed pediatric oncology training at Dana-Farber / Boston Children’s Hospital and obtained a Master of Science in Epidemiology from the Harvard School of Public Health. He is currently an Associate Professor of Pediatrics at Harvard Medical School. He is the Director of Experimental Therapeutics at Dana-Farber / Boston Children’s Cancer and Blood Disorders Center where he leads a program designed to bring new targeted therapies to children with cancer.
Dr. DuBois leads an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts clinical trials of novel targeted agents relevant to these diseases, including national phase 1, 2, and 3 clinical trials. He also studies new biomarkers that improve our understanding of the biology of pediatric solid tumors and of the pharmacodynamic effects of targeted therapies.
Dr. DuBois has served on a number of national committees, including the Children’s Oncology Group (COG) Neuroblastoma Steering Committee, COG Bone Tumor Committee, the American Society of Clinical Oncology (ASCO) Scientific Program Committee, and the US FDA Pediatric Oncology Drugs Advisory Committee (ODAC).
Dr. Christopher Gocke is an Associate Professor of Pathology and Oncology at the Johns Hopkins University School of Medicine. He is Director of the Division of Molecular Pathology, Deputy Director (Vice Chairman) of Personalized Medicine for the Department of Pathology, and Co-director of Johns Hopkins Genomics.
He received his B.A. in chemistry from Princeton University and his M.D. in 1985 from Rutgers Medical School. His residency training in pathology was at the University of Rochester and Stanford University, where he was Chief Resident. He completed a fellowship in pathology at Stanford.
Dr. Gocke has co-authored over 125 peer-reviewed publications in the area of cancer diagnostics. He is a past councilor on the Program Directors’ Council of the Association of Molecular Pathology and a member of the NCI’s Investigational Drug Steering Committee. He is Co-principle Investigator on two NIH research project cooperative agreements. He is board certified in Molecular Genetic Pathology and Anatomic Pathology.
Dr. Khasraw is a Medical Oncologist and Neurooncologist at Duke's Preston Robert Tisch Brain Tumor Center. He is also the Deputy Director of the newly established Center for Cancer Immunotherapy, tasked to speed up clinical research and translation for scientists across all departments at Duke who have made discoveries that show promise for developing new immunotherapies.
Dr. Khasraw has trained and worked in several countries, he received his MBChB from Salahaddin University, Kurdistan, Iraq, followed by an M.D. from Groningen University, the Netherlands. He moved to Australia and completed his medical oncology training at Royal North Shore Hospital in Sydney and subsequently completed an additional fellowship at Memorial Sloan-Kettering Cancer Center in New York.
Prior to joining Duke in September, 2019, Mustafa Khasraw worked as a medical oncologist in Sydney, Australia where he was also as a Clinical Lead at the Australian National Health & Medical Research Council Clinical Trial Centre at The University of Sydney where he has an ongoing honorary professorship in oncology.
He has a leading role in several clinical and translational programs and leads clinical trials with significant laboratory collaborations. He is interested in innovative trials designed to improve outcome of cancer patients. He is lead principal investigator on phase I, II and III multi-centre clinical trials for a number of pharmaceutical and academic groups.
He is a Fellow of the Royal Australasian College of Physicians as well as being an Elected Fellow of the Royal College of Physicians (Lon, UK).
Lincoln Nadauld, M.D., Ph.D. is the Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system located in the Intermountain West. Dr. Nadauld oversees the clinical implementation of genomic cancer medicine across Intermountain Healthcare’s 22 hospitals and 180 physician clinics.
Dr. Nadauld completed his undergraduate education at Brigham Young University and went on to complete combined M.D./Ph.D. and clinical training at the University of Utah. He completed additional clinical training in Medical Oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics. While at Stanford, Dr. Nadauld received the prestigious Young Investigator Award from the American Society of Clinical Oncology, and a Career Development Award from the National Cancer Institute. He remains on the research faculty at Stanford University School of Medicine focusing on cancer genomics and personalized cancer medicine. His work has been published extensively in journals such as Nature Medicine, Journal of Clinical Oncology, and Genome Medicine. He also serves on the board of directors of the Gastric Cancer Foundation and regularly reviews grant applications on behalf of the Department of Defense.
In 2016, Dr. Nadauld participated in the Precision Medicine Initiative Summit and roundtables at the White House with former President Barack Obama. He also attended former Vice President Joe Biden’s Cancer Moonshot Summit, where the Oncology Precision Network (OPeN), spearheaded by Dr. Nadauld, was mentioned among the Vice President’s remarks. OPeN is a consortium of healthcare partners working to advance data-sharing in precision medicine, including genomic information and outcomes.
Dr. Nadauld is married with five children, and enjoys attending their many activities and events, water sports, fishing and other athletic pursuits.
Dr. Park attended The University of Chicago for his A.B. degree, followed by dual training at The University of Pennsylvania School of Medicine where he received both his M.D. and Ph.D. degrees in 1995. Dr. Park then trained in internal medicine and hematology/oncology at The Hospital of The University of Pennsylvania prior to coming to Johns Hopkins where he completed a post-doctoral fellowship in cancer genetics in the laboratory of Drs. Ken Kinzler and Bert Vogelstein. In 2002, Dr. Park joined the faculty as an Assistant Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins where he is developing new therapeutics and diagnostics for breast cancer using genetic based approaches. He is currently Professor of Oncology in the Breast and Ovarian Cancer Program at Johns Hopkins and the Associate Director of the Hematology/Oncology Fellowship Training Program and Associate Director for Research Training and Education.
Dr. Milan Radovich, PhD, is an Associate Professor at the Indiana University School of Medicine (IUSM) and Vice President for Oncology Genomics at Indiana University Health (IUH). He is also co-director of the IU Health Precision Genomics Program, a clinical program dedicated to the integration of cutting-edge genomics for the care of metastatic cancer patients.
As an NCI-funded investigator, his research expertise focuses on the use of genomics in translational oncology. In particular, his research concentrates on the use of genomics in clinical studies, genomically-informed drug combinations, circulating biomarkers of cancer detection, and creating novel bioinformatic pipelines for cancer genome analyses. His laboratory has long standing-expertise in the research of triple-negative breast cancer, thymic malignancies, and cancer precision medicine.
As IUH Vice President for Oncology Genomics and co-director of the IU Health Precision Genomics Program, he co-leads a clinical service line that uses genomics to guide therapy for cancer patients. This program has sequenced over 5000 patients to date. With five clinics across the state of Indiana, the program provides access to cutting-edge genomic-based cancer care for patients.
Dr. Radovich is passionate about providing the best care to patients through precision medicine. He actively engages with patient advocacy, philanthropic groups, and mentoring to bring genomics research to patients. He is also actively involved in national precision medicine research as the ORIEN network scientific committee co-chair, a member of the Big Ten Cancer Research Consortium Basket Trials Working Group, and also served in the NCI Cancer Genome Atlas (TCGA). When he is not in the cancer center or in the lab, he enjoys spending time with his family. As a native Chicagoan and Purdue graduate, he also enjoys cheering on the Bears and Boilermakers.
Dr. Ryan Sullivan is board certified in Medical Oncology and an Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH). He attended Colby College for undergraduate studies and then matriculated to the University of Connecticut Medical School, graduating in 2001. He first trained in Internal Medicine at Mount Auburn Hospital in Cambridge, MA and then at Beth Israel Deaconess Medical Center (BIDMC) in Hematology/Oncology. At the MGH, he is the Associate Director of the Melanoma Program in the MGH Cancer Center and a member of the Termeer Center for Targeted Therapy. Dr. Sullivan is an active clinical and translational investigator whose main areas of interest are the development of novel molecular targeted and immunotherapeutic combinations for malignant melanoma, the translation of promising preclinical findings into early stage clinical trials, and the development of predictive biomarkers for these investigational as well as standard treatment approaches. In addition, he has an active interest in improving the prediction, through the development of blood-based biomarkers, and management of immune checkpoint inhibitor toxicity.
Prof Thomas is Head of the Cancer Theme at the Garvan Institute of Medical Research, and Director of The Kinghorn Cancer Centre. He is a NHMRC Principal Research Fellow and medical oncologist whose focus is on the application of genomic technologies to the understanding and management of cancer. Prof Thomas founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Dr Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centers in 7 countries, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. He has over 150 research publications, including lead or senior author papers in Cancer Cell, Molecular Cell, Journal of Clinical Investigation, Lancet Oncology, JAMA Oncology, and Journal of Clinical Oncology. Since moving to NSW, he has established the Australian Genomic Cancer Medicine Centre, a national precision medicine program for patients with rare and early onset cancers. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.
Christine M. Walko graduated with her Pharm.D. degree from Duquesne University in Pittsburgh, Pennsylvania, and completed a pharmacy practice residency at the Medical College of Virginia/VCU in Richmond, Virginia, and a hematology/oncology specialty residency at the University of North Carolina (UNC). She stayed at UNC to complete a two-year academic oncology fellowship focused on drug metabolism and translational research before taking an assistant professor position at UNC in the Division of Pharmacotherapy and Experimental Therapeutics. Dr. Walko is now a Personalized Medicine Specialist, Attending for the Personalized Medicine Consult Service and Chair of the Clinical Genomics Action Committee (CGAC), Moffitt's Molecular Tumor Board. She also serves on the ASCO TAPUR Molecular Tumor Board. Her research focus is on optimizing drug therapy using pharmacogenomics and pharmacokinetics to personalize intravenous and oral anticancer therapy for patients with cancer.